Literature DB >> 10943728

Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats.

C Corsi1, A Melani, L Bianchi, F Pedata.   

Abstract

The effect of the adenosine A2A receptor antagonist SCH 58261 on glutamate release was investigated in the striatum of young and old rats by microdialysis experiments. SCH 58261 (50 nM) significantly decreased the spontaneous and K+-evoked glutamate outflow in young rats. In aged rats, spontaneous glutamate outflow was significantly reduced in comparison to young rats and SCH 58261 significantly increased spontaneous and K+-evoked glutamate outflow. It is suggested that the opposite effects of the A2A antagonist on glutamate outflow in young and aged rats can be respectively attributed to blockade of striatal A2A adenosine receptors located on glutamatergic terminals and on the striatal indirect output pathway.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10943728     DOI： 10.1097/00001756-200008030-00048

Source DB:  PubMed          Journal:  Neuroreport        ISSN： 0959-4965            Impact factor:   1.837


  15 in total

Review 1.  Emerging therapies in the pharmacological treatment of Parkinson's disease.

Authors:  Amos D Korczyn; Miri Nussbaum
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Adenosine A2A receptors in the nucleus accumbens bi-directionally alter cocaine seeking in rats.

Authors:  Casey E O'Neill; McKenzie L LeTendre; Ryan K Bachtell
Journal:  Neuropsychopharmacology       Date:  2011-12-14       Impact factor: 7.853

3.  Neuroprotection induced by the adenosine A2A antagonist CSC in the 6-OHDA rat model of parkinsonism: effect on the activity of striatal output pathways.

Authors:  Jordi Bové; Jordi Serrats; Guadalupe Mengod; Roser Cortés; Eduardo Tolosa; Concepció Marin
Journal:  Exp Brain Res       Date:  2005-06-21       Impact factor: 1.972

4.  Adenosine A(1) receptor: Functional receptor-receptor interactions in the brain.

Authors:  Kathrin Sichardt; Karen Nieber
Journal:  Purinergic Signal       Date:  2007-09-05       Impact factor: 3.765

5.  Blockade of striatal adenosine A2A receptor reduces, through a presynaptic mechanism, quinolinic acid-induced excitotoxicity: possible relevance to neuroprotective interventions in neurodegenerative diseases of the striatum.

Authors:  Patrizia Popoli; Annita Pintor; Maria Rosaria Domenici; Claudio Frank; Maria Teresa Tebano; Antonella Pèzzola; Laura Scarchilli; Davide Quarta; Rosaria Reggio; Fiorella Malchiodi-Albedi; Mario Falchi; Marino Massotti
Journal:  J Neurosci       Date:  2002-03-01       Impact factor: 6.167

6.  Stimulation of adenosine receptors in the nucleus accumbens reverses the expression of cocaine sensitization and cross-sensitization to dopamine D2 receptors in rats.

Authors:  Benjamin D Hobson; Kathryn E Merritt; Ryan K Bachtell
Journal:  Neuropharmacology       Date:  2012-06-28       Impact factor: 5.250

7.  Transient Adenosine Release Is Modulated by NMDA and GABAB Receptors.

Authors:  Michael D Nguyen; Ying Wang; Mallikarjunarao Ganesana; B Jill Venton
Journal:  ACS Chem Neurosci       Date:  2017-01-30       Impact factor: 4.418

8.  Selective adenosine A2A receptor agonists and antagonists protect against spinal cord injury through peripheral and central effects.

Authors:  Irene Paterniti; Alessia Melani; Sara Cipriani; Francesca Corti; Tommaso Mello; Emanuela Mazzon; Emanuela Esposito; Placido Bramanti; Salvatore Cuzzocrea; Felicita Pedata
Journal:  J Neuroinflammation       Date:  2011-04-12       Impact factor: 8.322

9.  Neuroprotection by adenosine in the brain: From A(1) receptor activation to A (2A) receptor blockade.

Authors:  Rodrigo A Cunha
Journal:  Purinergic Signal       Date:  2005-03-17       Impact factor: 3.765

10.  The role of ATP and adenosine in the brain under normoxic and ischemic conditions.

Authors:  F Pedata; A Melani; A M Pugliese; E Coppi; S Cipriani; C Traini
Journal:  Purinergic Signal       Date:  2007-10-11       Impact factor: 3.765
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.